AMPK (AMP-activated protein kinase) is a central cellular energy sensor that coordinates metabolic pathways to maintain energy homeostasis[^1]. In the nervous system, AMPK plays critical roles in neuronal metabolism, synaptic plasticity, and has emerged as an important therapeutic target in neurodegenerative diseases[^2].
AMPK is a heterotrimeric complex consisting of:
- Catalytic α subunit (PRKAA1/α1, PRKAA2/α2)
- Regulatory β subunit (PRKAB1/β1, PRKAB2/β2)
- Regulatory γ subunit (PRKAG1/γ1, PRKAG2/γ2, PRKAG3/γ3)
The different isoforms form multiple AMPK complexes with tissue-specific distribution[^3].
AMPK has a heterotrimeric structure:
The N-terminal kinase domain:
- Contains the active site
- Regulated by phosphorylation (Thr172)
- Binds to β and γ subunits
The central region:
- Contains carbohydrate-binding module (CBM)
- Mediates subcellular localization
- Forms the structural core
The C-terminal region:
- Contains AMP/ATP binding sites
- Senses cellular energy status
- Allosteric regulation site[^4]
AMPK is activated by:
- Low ATP/AMP ratio
- Increased AMP
- Various metabolic stresses
- Exercise and muscle contraction
Once activated, AMPK:
- Activates catabolism (glucose uptake, fatty acid oxidation)
- Inhibits anabolism (lipid synthesis, protein synthesis)
- Increases mitochondrial biogenesis
In neurons, AMPK regulates:
- Synaptic plasticity
- Autophagy
- Neurogenesis
- Response to metabolic stress
- Mitochondrial function[^5]
AMPK has complex roles in AD:
- Activates autophagy to clear amyloid-beta
- Modulates tau phosphorylation
- Neuroprotective in animal models
- Reduced AMPK activity in AD brains
In PD:
- Protects dopaminergic neurons
- Activated by mitochondrial toxins
- Autophagy activation clears alpha-synuclein
- Therapeutic potential in PD models
In motor neuron disease:
- Dysregulated AMPK in ALS models
- Contributes to metabolic dysfunction
- Targeting shows promise in preclinical studies
AMPK is a key target in:
- Type 2 diabetes
- Metabolic syndrome
- Obesity[^6]
Therapeutic strategies include:
- AMPK activators: AICAR, metformin, AMPK-directed drugs
- Autophagy enhancers: Activate AMPK-mediated clearance
- Metabolic modulators: Improve neuronal energy status
- Exercise mimetics: Activate AMPK pathway[^7]
- Hardie et al., AMPK function (2012)
- Cai et al., AMPK in neurodegeneration (2019)
- Zhang et al., AMPK and autophagy (2018)
- Weisová et al., AMPK in neuronal survival (2019)
- Hardie et al., AMPK: a central metabolic sensor and regulator (2012)
- Cai et al., AMPK in neurodegeneration: therapeutic potential (2012)
- Zhang et al., AMPK activation as therapeutic strategy in AD (2016)
- Ronnett et al., AMPK, mTOR, and translation regulation in neurodegeneration (2009)
- Greer et al., AMPK in synaptic plasticity and memory (2007)
- Kang et al., AMPK and mitochondrial dynamics in PD (2020)